Cargando…
P2y(12) inhibitor monotherapy after 1–3 months dual antiplatelet therapy in patients with coronary artery disease and chronic kidney disease undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials
INTRODUCTION: In patients with coronary artery disease (CAD) and chronic kidney disease (CKD) undergoing percutaneous coronary intervention (PCI), whether short-term dual antiplatelet therapy (DAPT) followed by P2Y(12) inhibitors confers benefits compared with standard DAPT remains unclear. This stu...
Autores principales: | Yu, Yanqiao, Pan, Deng, Bai, Ruina, Luo, Jinwen, Tan, Yu, Duan, Wenhui, Shi, Dazhuo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357506/ https://www.ncbi.nlm.nih.gov/pubmed/37485257 http://dx.doi.org/10.3389/fcvm.2023.1197161 |
Ejemplares similares
-
Dual antiplatelet therapy following percutaneous coronary intervention: protocol for a systematic review
por: Elliott, Jesse, et al.
Publicado: (2019) -
Optimal duration of dual antiplatelet therapy following percutaneous coronary intervention: protocol for an umbrella review
por: Elliott, Jesse, et al.
Publicado: (2017) -
Reduction or de-escalation of dual antiplatelet therapy intensity or duration in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A mini-review
por: Farag, Mohamed, et al.
Publicado: (2022) -
Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry
por: Christ, Günter, et al.
Publicado: (2014) -
Dual Loading Antiplatelet Therapy in Patients With Acute Coronary Syndrome and High Bleeding Risk Undergoing Percutaneous Coronary Intervention: Findings From the Improving Care for Cardiovascular Disease in China Project
por: Yan, Yan, et al.
Publicado: (2022)